- 全部删除
您的购物车当前为空
Valiglurax (VU2957),也称为 VU0652957和 VU2957,是一种强效、选择性、中枢神经系统渗透剂,可口服生物利用的 mGlu4正变构调节剂。VU2957具有良好的跨物种的体内外药理学和药代动力学性质。VU2957被评估为治疗帕金森病的临床前开发候选药物。


为众多的药物研发团队赋能,
让新药发现更简单!
Valiglurax (VU2957),也称为 VU0652957和 VU2957,是一种强效、选择性、中枢神经系统渗透剂,可口服生物利用的 mGlu4正变构调节剂。VU2957具有良好的跨物种的体内外药理学和药代动力学性质。VU2957被评估为治疗帕金森病的临床前开发候选药物。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 2 mg | ¥ 108 | In stock | |
| 5 mg | ¥ 187 | In stock | |
| 10 mg | ¥ 310 | In stock | |
| 25 mg | ¥ 667 | In stock | |
| 50 mg | ¥ 993 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 207 | In stock |
Valiglurax 相关产品
| 产品描述 | Valiglurax (VU2957), also known as VU0652957 and VU2957, is a potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM. VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease. |
| 体内活性 | Valiglurax (0.3-30 mg/kg; po) reversed haloperidol-induced catalepsy (HIC) in rats[1]. |
| 别名 | VU-2957, VU2957, VU-0652957, VU0652957, VU 2957, VU 0652957 |
| 分子量 | 329.28 |
| 分子式 | C16H10F3N5 |
| CAS No. | 1976050-09-5 |
| Smiles | C(F)(F)(F)C=1C2=C(C=C(NC=3C=4C(NN3)=NC=CC4)C=C2)C=CN1 |
| 密度 | 1.530 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 112.5 mg/mL (341.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (12.15 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容